Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice
Ullah, I.; Escudie, F.; Scandale, I.; Gilani, Z.; Gendron-Lepage, G.; Gaudette, F.; Mowbray, C.; Fraisse, L.; Bazin, R.; Finzi, A.; Mothes, W.; Kumar, P.; Chatelain, E.; Uchil, P. D.
Show abstract
Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that evolve to escape spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or Main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy did not eliminate SARS-CoV-2 in mice. However, targeting two viral enzymes by combining molnupiravir with nirmatrelvir resulted in superior efficacy and virus clearance. Furthermore, combining molnupiravir with Caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma yielded rapid virus clearance and 100% survival. Thus, our study provides insights into treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 96%
- A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions 96%
- An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variants 96%
Similar papers in this journal
- The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice 95%
- Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses 95%
- Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections 95%
Similar papers in this journal
- Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro 96%
- Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses 95%
- Elucidating the Mechanism by Which HIV-1 Nucleocapsid Mutations Confer Resistance to Integrase Strand Transfer Inhibitors 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.